What Is Unique About Pharmaceuticals?
Small-molecule medicines remain the backbone of modern pharmacotherapy. But they encompass a broader regulatory landscape than most might think. A small-molecule development may need to navigate centralised, decentralised, or mutual recognition procedures, each with different assessment mechanics, timelines, and strategic trade-offs. Innovative molecules and orphan medicines must go through the centralised procedure at EMA. Each regulatory submission must undergo an assessment for paediatric requirements and, where applicable, a Paediatric Investigation Plan or Waiver must be agreed with PDCO to allow for MAA validation. Generics, established-use products, and many line extensions can use decentralised or mutual recognition routes, but choosing the wrong route creates delays that are difficult to reverse.
The EU pharmaceutical legislation is also undergoing its most significant overhaul in two decades. The new Pharmaceutical Directive and Regulation, politically agreed in December 2025, will reshape data protection periods, market exclusivity incentives, and supply obligations once it enters into force (expected mid-2026, with an approximately two-year transition period). Developers with active pipelines need to understand how these changes affect their filing strategy, particularly the modulated exclusivity framework that ties additional protection to criteria such as unmet medical need, comparative clinical evidence, and EU-based research activities.
Beyond authorisation route, the product subcategories within "pharmaceuticals" each carry distinct requirements. Generics must demonstrate bioequivalence or justify a BCS-based biowaiver under ICH M9 criteria. Herbal medicines follow traditional use registration or well-established use pathways, each demanding a full quality dossier plus documented evidence of long-standing safe use. Orphan medicines carry specific designation requirements, including prevalence thresholds and a significant-benefit assessment, alongside modified exclusivity periods under the new legislation. And Rx-to-OTC switches require safety evidence that the product can be used safely without medical supervision, supported by appropriate pack sizes and dosage adjustments. Each of these subcategories has its own regulatory logic, and treating them as variations of the same process is a common source of delay.
This page covers chemically synthesised and semi-synthetic small-molecule medicines, including innovator products, generics, herbal medicines, and orphan drugs (Rx and OTC). For biologics and biosimilars, see Biologics. For advanced therapy medicinal products, see ATMPs. For combination products that pair a medicine with a device component, see Combination Products.
Common Challenges and How We Help
"We don't know which authorisation route fits our product and commercial strategy."
We assess your molecule, indication, target markets, and competitive landscape to determine whether a centralised, decentralised, mutual recognition, or national procedure is the right fit. We then prepare the regulatory roadmap and coordinate the submission.
"Our generic needs bioequivalence data, but we think a biowaiver may be possible."
We evaluate BCS classification, dissolution profiles, and excipient comparability against ICH M9 criteria. Where a biowaiver is justified, we prepare the scientific justification. Where it is not, we design and manage the bioequivalence study programme.
"We want to switch our prescription product to OTC, but the evidence requirements are unclear."
We compile the safety and efficacy data needed to demonstrate suitability for self-medication, propose appropriate pack sizes and doses, and prepare the reclassification dossier for submission to national competent authorities.
"Our herbal product has a long history of use, but we don't know which regulatory pathway applies."
We determine whether a traditional use registration, well-established use authorisation, or stand-alone application is appropriate, assemble the bibliographic and quality evidence, and compile the dossier.
"We're developing an orphan medicine and need to understand the designation process and incentives."
We prepare orphan designation applications to the EMA Committee for Orphan Medicinal Products, and manage centralised submissions. We also advise on how the evolving exclusivity framework under the new EU pharmaceutical legislation affects your product's commercial protection.
"We're developing a new indication for an approved product and are not sure whether this triggers paediatric requirements."
We review each regulatory submission for paediatric requirements, and based on the assessment, we support you in meeting these requirements promptly. This helps avoid delays during the validation process caused by missing paediatric documentation (agreed Paediatric Investigation Plan, Waiver, or compliance check).
Applicable Services Across the Development Journey
Discovery & Concept
Regulatory classification (Rx, OTC, herbal, orphan). Initial regulatory roadmap: centralised, decentralised, mutual recognition, or national procedure. Target product profile review. Feasibility assessment for intended markets.
Preclinical
Preclinical development support (toxicology, safety pharmacology). Early CMC planning, including bioequivalence strategy and BCS biowaiver evaluation. Initial QMS setup and SOP development. Vendor qualification for active substance suppliers.
Design & Development
Pharmaceutical development and CMC: process development, formulation, analytical method development. Medical and scientific writing. Regulatory strategy and operations: Scientific Advice preparation, pre-submission meetings with EMA or national authorities. QMS implementation and deviation/CAPA management.
Clinical
Clinical development and medical monitoring. Protocol writing, Investigator's Brochure preparation, CTD Module 2.5/2.7 drafting. Clinical supply chain quality oversight. Pharmacovigilance setup for clinical trials.
Regulatory Submission & Approval
Dossier preparation and compilation across CTD Modules 1 to 5. Complete Module 3 authoring. GMP and QMS readiness reviews ahead of submission. Market access and HTA strategy development. Regulatory interactions and response to authority questions.
Launch & Market Access
Market access execution: HTA submissions, pricing, and reimbursement procedures. Variations and line extensions. Pharmacovigilance system establishment. Product information, labelling, and promotional material compliance.
Post-Market & Lifecycle Management
Pharmacovigilance operations: PSURs, signal detection, risk management plans. Post-approval variations and renewal management. Due diligence support for acquisitions and divestitures. Ongoing GMP/GDP audits and quality compliance. Rx-to-OTC switch programmes.
Example Projects
Centralised Approval for a Rare-Disease Therapy
A biotech developing a novel small-molecule treatment for a life-threatening neurological disorder needed orphan designation and a centralised marketing authorisation. regenold prepared the orphan designation dossier, supported Paediatric Investigation Plan negotiations, and coordinated the CHMP assessment process. The product received EU-wide approval within the target timeline, securing market exclusivity.
Rx-to-OTC Switch Across Multiple EU Markets
A mid-sized pharmaceutical company sought to reclassify a prescription analgesic to OTC status in several EU Member States. regenold evaluated the safety profile, proposed revised pack sizes and dose strengths to satisfy self-medication criteria, managed the literature review, and prepared national applications. The medicine was reclassified in five Member States within 12 months.
BCS Biowaiver Justification for a Generic Solid Oral Dosage Form
A generics manufacturer needed to demonstrate bioequivalence for a BCS Class I compound but wanted to avoid a full clinical bioequivalence study. regenold assessed solubility, permeability, and dissolution data against ICH M9 criteria, identified an excipient risk that required additional justification, and prepared the biowaiver dossier. The application was accepted without a request for an in vivo study.
Developing a Pharmaceutical Product?
Tell us about your molecule, your target markets, and where you are in development. We will assess the regulatory pathway and outline how we can support your programme.
Speak with an ExpertFrequently Asked Questions (FAQ)
Which EU authorisation route should I choose for my small-molecule medicine?
The centralised procedure is mandatory for innovative medicines, orphan medicines, and products for certain therapeutic areas (HIV, cancer, neurodegenerative diseases, diabetes, autoimmune disorders, and viral diseases). For generics, well-established use products, and products targeting fewer markets, the decentralised or mutual recognition procedure is often more efficient. The right choice depends on your molecule, your indication, and your commercial strategy. We assess all three factors before recommending a route.
Can I avoid a bioequivalence study for my generic?
Potentially. Under ICH M9 (implemented in both EMA and FDA jurisdictions), BCS Class I and Class III drugs may qualify for a biowaiver if stringent solubility, permeability, dissolution, and excipient criteria are met. We evaluate eligibility, identify potential obstacles early, and prepare either the biowaiver justification or a bioequivalence study design.
How will the new EU pharmaceutical legislation affect my product's data protection?
The reformed legislation introduces a modulated exclusivity framework. The baseline is eight years of data protection plus one year of market protection. Extensions of up to eleven years total are available if certain conditions are met, including addressing unmet medical need, conducting comparative clinical trials, or performing EU-based research. The final legal text is expected to be formally adopted in 2026, with a transition period of approximately two years. We help developers model the impact on their specific pipeline and adjust filing strategies accordingly.
What qualifies my product as an orphan medicine?
The product must be intended for a life-threatening or chronically debilitating condition with a prevalence below 5 in 10,000 in the EU (or where, without incentives, the investment would not be recovered). It must also demonstrate a significant benefit over existing treatments. Designation is granted by the EMA Committee for Orphan Medicinal Products. Under the new legislation, baseline orphan market exclusivity is set at nine years, with eleven years available for breakthrough orphan products addressing diseases with no available treatment.
How are herbal medicines regulated in the EU?
Herbal medicinal products follow one of three pathways. Traditional use registration requires evidence of at least 30 years of medicinal use (including 15 years within the EU) and a full quality dossier, but no new clinical data. Well-established use authorisation requires published scientific literature demonstrating at least 10 years of established medicinal use with recognised efficacy and safety. Stand-alone or mixed applications allow submission of proprietary clinical data. All three routes require a complete quality dossier (CTD Module 3).
Do I need separate dossiers for EU and US markets?
Both the EU and the US use the CTD format, so much of the underlying data can be shared. However, regional requirements differ: Module 1 is entirely region-specific, and there are differences in clinical, CMC, and labelling expectations. We structure development programmes to maximise data reuse while meeting the specific requirements of each jurisdiction.
How does regenold handle multi-country submissions?
For decentralised and mutual recognition procedures, we coordinate the submission across the Reference Member State and all Concerned Member States, manage the assessment timeline, and handle deficiency responses. For global programmes, we coordinate with our regulanet® members and partners in 90+ countries to align submissions and manage parallel authority interactions under a single contract.